Navigating a New Era of
Alzheimer's Diagnosis and Care
Recent scientific advances have fundamentally changed how Alzheimer's disease is diagnosed, treated, and managed. These advances have ushered in a new dawn of optimism and hope.
Biomarkers make timely detection of Alzheimer's disease possible
A biomarker is a measurable indicator in the body that can help clinicians identify and monitor Alzheimer’s disease, providing valuable insights for diagnosis and personalized treatment approaches. Using biomarkers can help us understand what is happening in the brain long before cognitive changes occur.
Our innovative test, ALZpathDx, uses a biomarker called pTau217, and provides a less invasive approach to detect and monitor Alzheimer’s disease with greater convenience and accessibility.
Disease-modifying therapies are revolutionizing treatment opportunities for Alzheimer's Disease
New therapies target the biology of Alzheimer’s disease – amyloid plaques and tau tangles – rather than cognitive symptoms. Recent accelerated FDA approval of two amyloid-targeted antibody treatments, ADUHELM® (aducanumab) and LEQEMBI™ (lecanemab), provide promise to not only reduce the toxic protein amyloid in the brain, but to potentially slow the progression of Alzheimer’s disease. Many clinical trials are enrolling people with Alzheimer’s disease who are showing no symptoms or only mild symptoms. This provides the greatest chance of slowing Alzheimer’s disease in its tracks.
